Zeo ScientifiX, Inc. (ZEOX) Form 8-K — Oct 30, 2026
$ZEOXForm 8-KItems 1.01, 3.02, 9.01Filed Oct 30, 2026, 8:30 AM ET0001829126-26-011800Original filing
Zeo ScientifiX (ZEO) signed a definitive Partnership Agreement with Nasdaq- and TASE-listed Pluri Inc. to license Pluri's 3D cell expansion technology for U.S. manufacturing and commercialization of its regenerative medicine portfolio in a license-for-equity transaction announced October 26, 2026. At closing, ZEO will issue Pluri shares equal to 41% of its outstanding common stock, plus 50 Series D non-convertible preferred shares carrying 51% of all voting power, with additional issuances bringing Pluri to 50% of ZEO post-closing.
Key figures
- Board size
- 7
- Max royalty rate
- 7.0% of Net Sales
- Tranche b shares
- 5% of outstanding upon 10-day VWAP of $5.50
- Warrant 1 shares
- 5% of outstanding at $4.00
- Warrant 2 shares
- 2.5% of outstanding at $5.50
- Liability cap zeo
- $1,500,000
- Liability cap pluri
- $2,000,000
- Pluri board nominees
- 4
- Severance multiplier
- 3 years of base compensation (5 years if market cap reaches $200,000,000)
- Series d voting power
- 51%
- Zeo to pluri exchange
- 5% of ZEO shares for 5% of Pluri shares
- Pluri post closing stake
- 50%
- Pluri initial equity stake
- 41%
- Selling shareholder exchange
- 4% of ZEO shares for 4% of Pluri shares
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.